Apramycin is a veterinary antimicrobial which appears to have lower intrinsic toxicity than aminoglycosides currently used for human therapy. This is because of increased selectivity for bacterial ribosomes (as opposed to eukaryotic cell and mitochondrial ribosomes). KP Smith tested apramycin's spectrum of activity against a large number of highly antibitoic resistant carbapenem-resistant Enterobacteriaceae and found broad and potent activity. Findings are described in a manuscript recently accepted into the journal, Diagnostic Microbiology and Infectious Disease.
Kirby Lab Blog